The @fda.gov has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with PSMA-positive metastatic androgen pathway modulation-naïve or-sensitive prostate cancer (mAPMN/S).
Link in the comments 👇
